Alemtuzumab, an anti-CD52 depletion antibody, is already FDA-approved for the treatment of multiple sclerosis and has potential for use in the treatment of acute lymphoblastic leukaemia and myeloid leukaemia [32–34]. This evidence concerns the gene CD52 and myeloid leukemia.